Wire · opportunities
FDA OKs Gene Therapy for Rare Neurodegenerative Disorder
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The FDA approved Fayuvi, the first gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA), a rare neurodegenerative disorder in children, offering a treatment that addresses the genetic cause. The approval follows resolution of prior manufacturing issues and includes warnings about potential serious side effects.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now pitch gene therapies for rare paediatric diseases as a viable treatment after FDA has shown flexibility despite earlier manufacturing hurdles. This opens a rare-disease drug market segment with high unmet needs and sets a precedent for similar therapies.
◆ Coverage
1 source · 18 Sep 2026
◆ Related on Wire
◆ Topics